

IMPACT OF DATA INTEGRITY ON PHARMACEUTICAL INDUSTRY ALCOA

Ms. Mallika Kalani*¹, Dr. Chhaya Shah²

*¹Student of K.B. Raval College of Pharmacy.

²Associate Professor in Department of Quality Assurance, K.B. Raval College of Pharmacy.

Article Received on 02 April 2026,
Article Revised on 22 April 2026,
Article Published on 01 May 2026,

<https://doi.org/10.5281/zenodo.19873546>

*Corresponding Author

Ms. Mallika Kalani

Student of K.B. Raval College of
Pharmacy.



How to cite this Article: Prof. Ashwini Shrikrushna Taware*, Dr. Chhaya Shah. (2026). Impact of Data Integrity on Pharmaceutical Industry Alcoa. World Journal of Pharmaceutical Research, 15(9), 37-46.
This work is licensed under Creative Commons Attribution 4.0 International license.

ABSTRACT

As well as being crucial for compliance reasons, ALCOA+ principles are becoming increasingly important to GMP (Good Manufacturing Practices). Their relevance is also growing as manufacturers in the life sciences sector continue to implement Industry solutions and processes. changed, duplicated, or moved. In terms of data integrity, data refers to all original records, including source data and metadata, whether they are kept on paper or electronically. ALCOA was suggested by various regulatory organisations, including the USFDA, Health Canada, and EMEA, to ensure the integrity of the data Attributable, Legible, Contemporaneous, Original and Accurate. In the pharmaceutical world, maintaining data integrity represents one of the most critical aspects of ensuring

that medications reach patients safely and effectively. This concept goes far beyond simple record keeping; it encompasses the entire journey of information from initial research through final product delivery, ensuring that every piece of data remains accurate, reliable, complete, and consistent throughout this process. The regulatory landscape has evolved significantly, with organizations like the FDA establishing comprehensive guidelines such as 21 CFR Part 11, alongside internationally recognized frameworks like ALCOA+ and ICH Q7. These standards emphasize that pharmaceutical data must be attributable, legible, contemporaneous, original, and accurate, while also being complete, consistent, enduring, and available whenever needed. The importance of data integrity extends well beyond regulatory compliance. When pharmaceutical companies maintain robust data practices, they build trust with patients, protect public health, and foster transparency across all operational levels.

However, the path to achieving this ideal is fraught with challenges, including human errors, inadequate digital infrastructure, poor documentation practices, and increasingly sophisticated cybersecurity threats. To address these challenges, companies are implementing comprehensive risk-based approaches, investing in advanced digital technologies, and cultivating organizational cultures that prioritize quality and accountability. This paper explores the fundamental principles governing data integrity, examines regulatory requirements, identifies common pitfalls, and presents best practices for maintaining data integrity in pharmaceutical operations.

KEYWORDS: Integrity, Data governance, ALCOA, Organisation culture, cyber security.

INTRODUCTION

Data integrity refers to the assurance that information remains accurate, complete, and unaltered, and that it is accessed or modified only by authorized individuals. In the pharmaceutical industry, data integrity is not defined by a single tool or system; rather, it is a holistic framework built on established standards, policies, processes, and procedures that are implemented across an organization and followed by employees, partners, and stakeholders. It is closely aligned with Good Documentation Practices (GDP), which form the foundation for reliable and traceable records. Strong data integrity practices contribute to the overall success and credibility of a company, while weak controls can compromise the quality of records and ultimately impact the safety and effectiveness of pharmaceutical products.

Data integrity principles apply to all elements of the Quality Management System and encompass both paper-based and electronic data. Manufacturers and distributors are responsible for ensuring effective data governance, especially during regulatory inspections. This includes identifying potential risks within data management systems, addressing vulnerabilities, and implementing appropriate controls to maintain data reliability. The ALCOA principles—Attributable, Legible, Contemporaneous, Original, and Accurate—serve as a widely accepted framework to ensure compliance with regulatory expectations. Additionally, the use of audit trails in electronic systems enhances transparency by recording any additions, deletions, or modifications without obscuring the original data, thereby enabling complete traceability and reconstruction of records when needed.

Data integrity fundamentally refers to the preservation of accuracy, completeness, and consistency of data throughout its entire lifecycle. In the pharmaceutical industry, this

concept is critically important, as information generated during drug development, manufacturing, and distribution has a direct impact on patient safety and the effectiveness of treatments. The industry operates in a highly regulated environment where all decisions must be supported by reliable and trustworthy data. From the initial stages of drug discovery to post-market surveillance, pharmaceutical companies produce large volumes of data that must be carefully controlled, maintained, and protected to ensure its reliability and compliance.

ALCOA principles

- **Attributable:** Maintaining data integrity relies on secure login practices, such as assigning unique user IDs and using electronic signatures to track all data-related activities. These measures ensure that every action within the system can be traced to a specific individual. Accurate data management also involves recording key details, including the identity of data collectors, individuals performing actions, and corresponding timestamps. Ensuring that only qualified personnel handle data, along with the use of compliant electronic systems that meet regulatory standards like 21 CFR Part 11, is critical for preserving data validity and integrity. Attributability is evaluated by determining how effectively each data entry or action is linked to the individual responsible for it. The attributable score represents the proportion of data correctly assigned to the appropriate staff member, thereby supporting transparency and accountability in data handling
- **Legible:** This process requires the use of secure, individual user accounts and electronic signatures to ensure traceability. Each user must have a unique login ID to maintain accountability, while the use of shared or generic credentials is strictly prohibited. All records should be clear and legible, with identifiable signatures, and should include both raw data and relevant metadata. Information must be accurate, well-structured, and easy to interpret. The use of ambiguous terms, jargon, or informal language that could lead to confusion over time should be avoided. Data should be maintained in electronic form using standardized formats, such as UTF-8 encoding. Numerical values must follow consistent formatting, and free-text entries should rely on standardized dictionary terms to ensure clarity and uniformity.
- **Contemporaneous:** This focuses on the importance of recording data promptly and accurately, whether it is generated by individuals or automated systems. Delays in documentation can result in errors, reduce accuracy, and negatively affect overall data quality. Contemporaneous recording is assessed by verifying that each entry includes the

correct date and time stamps. The contemporaneous score represents the proportion of data entries that contain accurate and timely timestamp information.

- **Original:** Original data, also referred to as source or primary data, may be recorded either on paper or in electronic form. It should always be preserved in its native format rather than relying on copies or transcriptions, especially in manual record-keeping processes. The authenticity of data is verified using a blockchain-based smart contract, which helps ensure that the records remain untampered. Data originality is then evaluated using a simple scoring system: a score of 100 is assigned if the data is confirmed to be original, while a score of 0 is given if any evidence of tampering is detected.
- **Accurate:** Accurate records should faithfully represent actual events without errors or inconsistencies. Any modifications must be properly documented and annotated to ensure transparency and maintain accountability. All measurements and observations should reflect true values, supporting both precision and reliability. Data accuracy is evaluated using validation methods such as range checks and outlier detection, ensuring that numerical values remain within acceptable limits.



Importance of data Integrity

In modern clinical trials, data integrity and regulatory compliance play a central role in the approval process. Regulatory authorities such as the U.S. Food and Drug Administration and the European Medicines Agency closely evaluate submissions to identify any potential data

integrity concerns. Such issues can directly affect the assessment of a drug or medical device's safety and effectiveness. They may arise from various sources, including human error, system failures, or intentional misconduct. Even when unintentional, these deficiencies are taken seriously, and regulatory bodies do not typically overlook them.

Non-compliance with data integrity standards can lead to significant regulatory actions, including warning letters and consent decrees. Historical analyses of FDA enforcement trends show that nearly 80% of data integrity-related warning letters issued since 2008 occurred between 2014 and 2018, underscoring the increasing emphasis regulators place on maintaining high standards of data integrity.

Regulatory Importance

1. Regulatory Oversight

Agencies like the FDA and EMA closely monitor data integrity and issue warning letters for non-compliance, including issues such as incomplete records and missing audit trails.

2. Supports Quality Culture

The framework promotes accountability, transparency, and traceability, helping organizations build a strong quality-driven culture.

3. Addresses Digital Transformation Challenges

Modern systems like electronic records, cloud storage, and AI/ML introduce complexities that ALCOA++ helps manage effectively.

4. Ensures Data Legibility and Endurance

Data remains readable and accessible over long periods, even with evolving technologies (e.g., long-term record retention).

5. Enhances Data Security

Protects data from cyber threats and unauthorized access, which is critical in digital environments

6. Improves Traceability

Maintains complete records of data changes, enabling tracking throughout the data lifecycle and supporting validation of automated or AI-driven processes.

7. Supports Digital Adoption

Many organizations are adopting digital solutions to meet ALCOA++ standards, highlighting its importance in modern pharmaceutical workflows

8. Prevents Data Manipulation and Fraud

Strong controls and audit trails ensure transparency and reduce the risk of data falsification or unauthorized changes.

9. Regulatory Alignment

ALCOA++ aligns with major regulatory frameworks such as FDA's 21 CFR Part 11, EMA's GxP guidelines, and ICH E6 (R3), ensuring compliance in clinical trials, manufacturing, and quality control.

Implementation of ALCOA data integrity

- **Stronger Control on Electronic Systems**

Implementation of advanced audit trails and validated electronic signature systems to ensure secure and traceable data handling.

- **Mandatory Audit Trail Reviews**

Regular review of audit trails is now required, ensuring continuous monitoring of data changes and system activities.

- **Third-Party Compliance Responsibility**

Cloud service providers (SaaS) must comply with GxP requirements, and organizations remain accountable even when using third-party systems.

- **Focus on Metadata Integrity**

Not only primary data, but also metadata (data about data) must remain complete, accurate, and unaltered.

- **Data Flow Process Mapping**

Clear mapping of how raw data moves through systems to final reports, ensuring transparency and traceability.

- **Automated Validation and Alerts**


Use of automated systems to validate processes and trigger alerts for any deviations in data handling.

- **Validation of AI/ML Systems**

Any AI or machine learning tools used must be validated to ensure compliance with data integrity requirements.

- **Promotion of Data Integrity Culture**

Regulatory expectations now include building a strong organizational culture focused on data integrity, not just technical compliance.



Mitigation Strategies

- **DATA GENERATION STAGE**

- ✓ Use validated instrument
- ✓ Ensure accurate time
- ✓ Assign unique user Credentials

- **DATA RECORDING STAGE**

- ✓ Record data contemporaneously
- ✓ Use Audit trails [Part-11]

- ✓ Prevent overwriting or deletion
- **DATA REVIEW STAGE**
 - ✓ Review by qualified personnel
 - ✓ Check for completeness and accuracy
 - ✓ Document any corrections
- **DATA APPROVAL STAGE**
 - ✓ Electronic signatures [Part-11]
 - ✓ Role based access control
 - ✓ Approval logs maintained
- **DATA ARCHIVAL STAGE**
 - ✓ Secure, validated storage
 - ✓ Backup and disaster recovery
 - ✓ Retention per regulatory norms
- **DATA RETRIEVAL AND AUDIT**
 - ✓ Traceable audit trails
 - ✓ Retrieval without data loss
 - ✓ Support for regulatory inspection

World Regulatory Recommendations For Data Integrity

USFDA (21 CFR)

The federal government publishes its regulatory requirements in the Code of Federal Regulations (CFR), which is updated annually. Title 21 of the CFR specifically contains the regulations established by the Food and Drug Administration (FDA). These regulations provide a comprehensive framework for ensuring the safety, efficacy, and quality of regulated products.

MHRA

Data integrity is a fundamental component of the pharmaceutical quality system, ensuring that medicinal products consistently meet required quality standards. The MHRA has issued guidelines on Good Manufacturing Practice (GMP) data integrity to strengthen existing European Union standards for both active pharmaceutical ingredients and finished dosage forms.

TGA

The Therapeutic Goods Administration (TGA) in Australia defines data integrity issues as deficiencies that may pose a significant risk to product quality and patient safety. Such deficiencies may arise from process failures or from instances where manufacturers have misrepresented, falsified, or fabricated data.

cGMP

In response to increasing concerns about data integrity breaches, the FDA has issued guidance on data integrity and compliance with current Good Manufacturing Practices (cGMP). Adherence to cGMP ensures robust record-keeping practices that prevent data loss, manipulation, or obscuration.

Good Documentation Practices (GDP)

Good documentation practices encompass a set of principles that ensure all records—whether electronic or paper-based—are attributable, legible, traceable, permanent, contemporaneous, original, and accurate. These practices collectively support the reliability, integrity, and regulatory compliance of data.

WHO: In the context of these suggestions, “good practices” refers to the techniques that collectively and separately ensure that documentation, whether electronic or paper, is accountable, legible, traceable, permanent, contemporaneously documented, original, and accurate. A critical stage in the process, which includes numerous participants and activities, is ensuring the accuracy and dependability of the data manufacturers give to national.

REFERENCES

1. Nikam, N. R.; Patil, P. R.; Vakhariya, M. R. R.; Mohite, D. S. K. DATA Integrity: An Overview, 2020; 11.
2. Hart, S. Data Integrity: TGA Expectations.
3. Rachel, P. K.; Gupta, N. V. Data Integrity – Regulations and Current Scenario. No. 05.
4. McLaughlin, E. Guidance for Industry. Quest. Answ, 2018.
5. Spilka, S. Data Integrity: Relevancy, Risks and the Appropriate Use. ANEXIABlog.<https://anexia.com/blog/en/data-integrity-relevancy-risks-and-the-appropriate-use/> (accessed)
6. In the context of the Memograph M RSG45 Data Manager combined with Field Data Manager (FDM) Analysis software.

7. World health organization: Expert committee on Specification oh pharmaceutical product. GENEVA Switzerland: WHO, 2025.
8. Cho, K.; Van Merriënboer, B.; Gulcehre, C.; Bahdanau, D.; Bougares, F.; Schwenk, H.; Bengio, Y. Learning phrase representations using RNN encoder-decoder for statistical machine translation. arXiv, 2014; arXiv:1406.1078
9. Patel, L.; Shukla, T.; Huang, X.; Ussery, D.W.; Wang, S. Machine learning methods in drug discovery. *Molecules*, 25: 5277.
10. Salkuti, S.R. A survey of big data and machine learning. *Int. J. Electr. Comput. Eng.* (2088–8708) 10, 575–580.
11. engupta, S.; Basak, S.; Saikia, P.; Paul, S.; Tsalavoutis, V.; Atiah, F.; Ravi, V.; Peters, A. A review of deep learning with special emphasis on architectures, applications and recent trends. *Knowl.-Based Syst*, 2020; 194: 105596.
12. IT Data Integrity Risk - Open Risk Manual. https://www.openriskmanual.org/wiki/IT_Data_Integrity_Risk (accessed 2023-04-20).
13. The Importance of Data Integrity for Your Business. *Commercient*. <https://www.commercient.com/the-importance-of-data-integrityfor-your-business/> (accessed 2023-04-20).
14. Oqotech. Causes of identified data integrity problems. *Oqotech*. <https://www.oqotech.com/en/blog/data-integrity-en/causes-of-dataintegrity-issues-identified-by-regulatory-agencies/> (accessed 2023-04-20).
15. Data-Integrity-in-the-Pharmaceutical-Industry.Pdf. <https://qbd.eu/wp-content/uploads/Data-Integrity-in-the-pharmaceutical-industry.pdf> (accessed 2023-04-20).